HeroImageHome-m2
layer22mobile


GET THE
LATEST DATA

Sign up to receive
the latest about
XIENCE study
results as they
become available.

Sign up

The Science Behind Xience Safety

XIENCE's unparalleled safety1-3 and superior performance is due to its unique design and fluoropolymer coating, as well as the elution of everolimus.

more

The Science Behind Xience Safety

XIENCE's unparalleled safety1-3 and superior performance is due to its unique design and fluoropolymer coating, as well as the elution of everolimus.

more

Xience Safety For Complex Patients

Multiple recent XIENCE trial results, with endpoints ranging from 1 to 3 years,4-7 reveal excellent safety data on stent thrombosis (ST) in left main disease, diabetes and other complex conditions.

more

Xience Safety For Complex Patients

Multiple recent XIENCE trial results, with endpoints ranging from 1 to 3 years,4-7 reveal excellent safety data on stent thrombosis (ST) in left main disease, diabetes and other complex conditions.

more

Experts' and Patient's point of view

To comparative
clinical data

XIENCE data8 showed “less ST compared to bare metal stents as well as first-generation and other second-generation stents . . . a repeatable finding in almost every study.”

Gregg Stone, MD

Play video

To comparative
clinical data

XIENCE data8 showed “less ST compared to bare metal stents as well as first-generation and other second-generation stents . . . a repeatable finding in almost every study.”

Gregg Stone, MD

Play video

To comparative
clinical data

XIENCE data8 showed “less ST compared to bare metal stents as well as first-generation and other second-generation stents . . . a repeatable finding in almost every study.”

Gregg Stone, MD

Play video

To comparative
clinical data

XIENCE data8 showed “less ST compared to bare metal stents as well as first-generation and other second-generation stents . . . a repeatable finding in almost every study.”

Gregg Stone, MD

Play video

Get the Latest Data

Sign up to receive the latest about XIENCE study results, as they become available.

AP2944530-WBO Rev. A

  1. Valgimigli M. Effects of cobalt-chromium everolimus eluting or bare metal stent on fatal and non-fatal cardiovascular events: a patient-level meta analysis. EuroPCR 2014.  
  2. Bangalore S, et al. BMJ. 2013;347:f6625. doi: 10.1136/bmj.f6625.
  3. Palmerini T, et al. JACC. 2014;63:299-307. doi: 10.1016/j.jacc.2013.09.061.
  4. Stone GW, et al. EXCEL Trial 3-year data. N Engl J Med. 2016;375:2223-2235. doi: 10.1056/NEJMoa1610227.
  5. Teeuwen K, et al. PRISON IV Trial 1-year data. JACC Cardiovasc Interv. 2016. doi: 10.1016/ j.jcin.2016.10.017.
  6. Kaul U. 2-Year TUXEDO Outcomes. TCT 2016.
  7. Lam, M. TWENTE Trial. Am Heart J.  2015;169:69-77. doi: 10.1016/j.ahj.2014.10.011. 
  8. Palmerini T, et al. Lancet. 2012:379:1393-1402.

You are about to leave the Abbott family of websites for a third party website.

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.

The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit the website?

Disclaimer

Xiencestent.com is a product-specific website that is NOT intended for U.S. residents. This web content is exclusively reserved for health care professionals in countries with applicable health authority product registrations.

If you are a resident of a country other than those to which the site is directed, please contact your local Abbott affiliate to obtain the appropriate product information for your country of residence.

Do you wish to continue to visit the International section of this website?